Hycamtin is owned by Novartis.
Hycamtin contains Topotecan Hydrochloride.
Hycamtin has a total of 1 drug patent out of which 0 drug patents have expired.
Hycamtin was authorised for market use on 11 October, 2007.
Hycamtin is available in capsule;oral dosage forms.
The generics of Hycamtin are possible to be released after 10 December, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8158645||NOVARTIS||Compound, corresponding compositions, preparation and/or treatment methods|| |
(1 year, 10 months from now)
Market Authorisation Date: 11 October, 2007
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic